ALLO - Pfizer: A 'New' Growth Foundation In Genomic Medicine

• Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps.
• Continuation of the policy of dividend growth is a stated priority.
• Biopharma led by scientific pipeline innovation is expected to generate $15 billion in new product revenue through 2025.
• Gene therapies led by three late-stage programs have favorable approval probability and are followed by 10 preclinic programs.
• Pfizer is scheduled to provide an update on their three late-stage gene therapy programs at ASH in December which could be a price catalyst.

For further details see: